Stock 2696 SHANGHAI HENLIUS BIOTECH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Shanghai Henlius Biotech, Inc. Stock

Equities

2696

CNE100003N76

Pharmaceuticals

Delayed Hong Kong S.E.
Other stock markets
 01:48:52 2024-12-06 am EST 		5-day change 1st Jan Change
21.95 HKD +2.09% Intraday chart for Shanghai Henlius Biotech, Inc. +2.09% +57.91%
Dec. 04 Henlius Gets Chinese Regulator's Go-Ahead for Phase 2 Clinical Trial of Tumor Drug MT
Dec. 04 Henlius Gets Chinese Regulator's Approval for Clinical Trial of Tumor Drug MT

Valuation: Shanghai Henlius Biotech, Inc.

Capitalization 10.9B 11.69B 1.5B 1.42B 1.32B 1.18B 2.11B 127B 2.33B 16.33B 6.06B 52.11B 5.64B 5.52B 225B P/E ratio 2024 *
18.3x
P/E ratio 2025 * 16.3x
Enterprise value 10.9B 11.69B 1.5B 1.42B 1.32B 1.18B 2.11B 127B 2.33B 16.33B 6.06B 52.11B 5.64B 5.52B 225B EV / Sales 2024 *
1.87x
EV / Sales 2025 * 1.75x
Free-Float
14.64%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data

Chart: Shanghai Henlius Biotech, Inc.

Dynamic Chart

Latest news: Shanghai Henlius Biotech, Inc.

Henlius Gets Chinese Regulator's Go-Ahead for Phase 2 Clinical Trial of Tumor Drug Dec. 04 MT
Henlius Gets Chinese Regulator's Approval for Clinical Trial of Tumor Drug Dec. 04 MT
Henlius Secures Chinese Regulator's Nod for New Drug Application for Breast Cancer Treatment Dec. 04 MT
Shanghai Henlius Biotech's NDA for Lung Cancer Drug's New Indication Gets Chinese Regulator's Nod Dec. 04 MT
Shanghai Henlius Biotech, Inc. Announces Application for the Phase 2 Clinical Trial of HLX22 Approved by the National Medical Products Administration Dec. 04 CI
Shanghai Henlius Biotech Announces Application for the Phase 1b/2 Clinical Trial of HLX43 for Injection Approved by the National Medical Products Administration Dec. 04 CI
Shanghai Henlius Biotech, Inc. Announces New Drug Application for Pertuzumab Biosimilar Hlx11 Has Been Accepted by the National Medical Products Administration Dec. 04 CI
Shanghai Henlius Biotech, Inc. Announces National Medical Products Administration Accepts New Drug Application for Pertuzumab Biosimilar HLX11 Dec. 04 CI
Alligator Biosciences' first patient dosed in phase 3 study with AC101 Dec. 04 FW
New Indication of Henlius' Lung Cancer Drug Given Green Light by Chinese Regulator Dec. 03 MT
Shanghai Henlius Biotech, Inc. Announces New Drug Application for New Indication of Hansizhuang (Serplulimab Injection) Dec. 03 CI
Henlius Announces First Shipment of Henlius Trastuzumab to Us Dec. 02 CI
Henlius Doses First Patient in Phase 3 Study of Combo Treatment for Gastric Cancer Nov. 22 MT
More news

Press Releases: Shanghai Henlius Biotech, Inc.

Alligator Announces First Patient Dosed in Shanghai Henlius Biotech, Inc. Phase 3 Clinical Trial Dec. 04 AQ
FDA Accepts BLA For Shanghai Henlius Biotech's And Organon's HLX14, A Denosumab Biosimilar Nov. 12 AQ
Shanghai Henlius Biotech, Inc. - First Patient in Japan Dosed for MRCT Phase 3 Study on First-Line mCRC of Henlius Anti-PD-1 mAb Serplulimab Oct. 25 AQ
Organon - Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta Biosimilar Candidate HLX11 Oct. 01 AQ
Henlius Receives Positive CHMP Opinion for HANSIZHUANG as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer Sep. 23 AQ
More press releases

Quotes and Performance

1 day+2.09%
1 week+2.09%
Current month+2.09%
1 month+4.03%
3 months-4.98%
6 months-2.44%
Current year+57.91%
More quotes

Course Extremes

1 week
21.30
Extreme 21.3
22.15
1 month
20.00
Extreme 20
22.15
Current year
12.20
Extreme 12.2
23.45
1 year
11.20
Extreme 11.2
23.45
3 years
9.60
Extreme 9.6
29.95
5 years
9.60
Extreme 9.6
67.05
10 years
9.60
Extreme 9.6
67.05
More quotes

Managers and Directors: Shanghai Henlius Biotech, Inc.

Director TitleAgeSince
Jun Zhu CEO
 Chief Executive Officer 46 2023-07-16
Wei Dong Jiang CTO
 Chief Tech/Sci/R&D Officer - 2009-11-30
Wei Huang PSD
 President 56 2023-09-30
Manager TitleAgeSince
Qi Yu Chen CHM
 Chairman 52 2018-11-30
Xiao Hui Guan BRD
 Director/Board Member 53 2018-12-23
Rui Lin Song BRD
 Director/Board Member 61 2019-09-01
More insiders

ETFs: Shanghai Henlius Biotech, Inc.

Name Weight AuM 1st Jan change Investor Rating
BMO MSCI GENOMIC INNOVATION INDEX ETF - CAD ETF BMO MSCI Genomic Innovation Index ETF - CAD
0.04% 2 M€ -.--%
BMO MSCI INNOVATION INDEX ETF - CAD ETF BMO MSCI Innovation Index ETF - CAD
0.01% 7 M€ -.--% -
More ETFs: Shanghai Henlius Biotech, Inc.

Biopharmaceuticals

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi. ($)
SHANGHAI HENLIUS BIOTECH, INC. Stock Shanghai Henlius Biotech, Inc.
+2.09%+2.09%+71.48%-14.59%1.5B
CSL LIMITED Stock CSL Limited
-0.31%-0.50%+4.99%-5.22%87.83B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+0.31%-3.60%+34.83%+7.11%48.47B
UCB Stock UCB
-1.49%+1.53%+153.49%+91.85%37.15B
BIOGEN INC. Stock Biogen Inc.
-1.03%-0.36%-30.63%-28.88%23.21B
INCYTE CORPORATION Stock Incyte Corporation
+0.40%-0.70%+36.67%+13.89%14.43B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-0.92%+5.93%+60.71%-35.92%13.3B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-0.53%+1.13%-29.32%-20.24%12.61B
ALTEOGEN INC. Stock ALTEOGEN Inc.
-2.20%+2.81%+317.45%+399.60%11.71B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
0.00%+1.11%+22.99%+80.29%9.76B
Average -0.37%+1.58%+64.27%+48.79% 26B
Weighted average by Cap. -0.49%+0.33%+46.67%+28.99%
See all sector performances

Financials

2024 *2025 *
Net sales 5.83B 6.25B 803M 759M 706M 629M 1.13B 67.99B 1.25B 8.73B 3.24B 27.85B 3.01B 2.95B 121B 6.22B 6.67B 857M 811M 754M 672M 1.2B 72.64B 1.33B 9.32B 3.46B 29.76B 3.22B 3.15B 129B
Net income 583M 625M 80.29M 75.97M 70.6M 62.95M 113M 6.8B 125M 873M 324M 2.79B 301M 295M 12.06B 648M 695M 89.28M 84.47M 78.5M 69.99M 125M 7.56B 139M 971M 360M 3.1B 335M 328M 13.41B
Net Debt - -
More financial data * Estimated data

Company Profile

Logo Shanghai Henlius Biotech, Inc.
Shanghai Henlius Biotech Inc. is a China-based company principally involved in the research, development, production and sales of monoclonal antibody products. The Company’s main products include rituximab injection HLX01 (Hanlikang), Herceptin (trastuzumab) biosimilar HLX02, Humira (adalimumab) biosimilar HLX03 and Avastin (bevacizumab) biosimilar HLX04, as well as bio-innovative drug candidates, including HLX06 (a novel VEGFR2 inhibitor), HLX07 (an EGFR inhibitor), HLX10 (a novel PD-1 inhibitor), HLX20 (a novel PD-L1 inhibitor) and HLX22 (a novel HER2 inhibitor), among others. The Company is also engaged in the provision of related technical services. The Company operates its businesses primarily in Mainland China and the United States.
Employees
3,546
Sector
Pharmaceuticals
Calendar
2025-03-30 - Q4 2024 Earnings Release (Projected)
More about the company

Quotes

Date Price Change Volume
24-12-06 21.95 $ +2.09% 133,000
24-12-05 21.50 $ -0.46% 28,400
24-12-04 21.60 $ 0.00% 86,000
24-12-03 21.60 $ +0.47% 19,412
24-12-02 21.50 $ 0.00% 12,300

Delayed Quote Hong Kong S.E., December 06, 2024 at 01:48 am EST

More quotes

Income Statement and Estimates

income-statement-evolution-chart SHANGHAI-HENLIUS-BIOTECH- More financial data

Ratings

Trading Rating
Investor Rating
ESG Refinitiv
surperformance-ratings-light-chart SHANGHAI-HENLIUS-BIOTECH-More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
20.06CNY
Average target price
18.57CNY
Spread / Average Target
-7.41%
Consensus
Profit revisions
estimates-change-chart SHANGHAI-HENLIUS-BIOTECH- Estimate revisions

Annual profits - Rate of surprise

quality-estimates-chart SHANGHAI-HENLIUS-BIOTECH- Company calendar
  1. Stock Market
  2. Equities
  3. 2696 Stock